Trial Profile

A phase 1 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of EP262 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 000262 (Primary)
Indications Atopic dermatitis; Chronic urticaria; Skin disorders
Focus Adverse reactions; First in man
Sponsors Escient Pharmaceuticals

Most Recent Events

20 Jun 2023 Results presented in the Escient Pharmaceuticals Media Release.
20 Jun 2023 Status changed to completed, according to an Escient Pharmaceuticals media release.
02 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com